Novel formulation
AssigneeBuzz Pharmaceuticals Limited
InventorsChris JONES, Darren GREEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to a transdermal patch comprising a pharmaceutical formulation, the formulation comprising ropivacaine or an opioid, a pharmaceutically-acceptable adhesive and optionally one or more excipients selected from the group consisting of carrier oils, penetration enhancers and hydrophilic materials. The present invention also relates to methods of preparation of such a pharmaceutical formulation, as well as the use of such a transdermal patch in the treatment of pain (e.g. nociceptive and/or neuropathic pain).
Claims32
A transdermal patch comprising a pharmaceutical formulation, said formulation comprising ropivacaine or an opioid and a pharmaceutically-acceptable adhesive, and wherein said formulation has an in vitro human skin permeation rate of ropivacaine or an opioid that is greater than 1.8 μg cm−2 h−1.
A transdermal patch comprising a pharmaceutical formulation, said formulation comprising:
- (i) ropivacaine or an opioid,
- (ii) a pharmaceutically-acceptable adhesive, and optionally
- (iii) one or more of either a penetration enhancer, a hydrophilic material, and a carrier oil having a ropivacaine or an opioid solubility of greater than or equal to 1.5% (w/w).
5-6. (canceled)
8-9. (canceled)
15-16. (canceled)
(canceled)
20-22.
(canceled)
26-27. (canceled)
(canceled)
31-37. (canceled)
39-40. (canceled)
(canceled)
45-51. (canceled)
Dependencies are inferred from the claim text.